Trial Profile
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Had Failed Prior Platinum Based Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Results (n=16 enrolled between 5 Aug 2017 and 13 Oct 2018) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 14 Jul 2017 New trial record